NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-23
Reading UTHR? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a stable, long-term thesis with a focus on durable revenue growth. The current state is mixed, with recent performance showing strength but also challenges in execution.
The market currently prices UTHR at a neutral valuation, suggesting that expectations are aligned with its recent performance. There is a low fragility tier, indicating that while execution quality is weak, it is not overly priced for significant turbulence.
Fundamentals may show mixed results in the near term, as management emphasizes growth despite recent revenue and operating income declines. The risk of missing future earnings remains moderate, given the company's history in a high-miss-rate industry.
The thesis hinges on management's ability to deliver on revenue growth and maintain operational efficiency. Additionally, the performance of sector bellwethers like HLN, TEVA, and ZTS will be crucial in determining the overall momentum in the Healthcare sector.
In the next 1 to 3 years, UTHR's performance will depend on management execution and sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The FDA approved a new lung device, supporting revenue growth. However, the latest earnings report showed a miss, which raises concerns.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Positive revenue growth in Q2 would show recovery from the recent earnings miss. It would also align with management's goal for double-digit growth.
Confirms:Q2 total revenues were over $800 million. This shows a return to growth.
Disproves:Q2 total revenues were below $780 million. This continues the decline.
Why it matters: The NDA could help Tyvaso treat idiopathic pulmonary fibrosis. This may increase growth.
Confirms:United Therapeutics plans to submit the NDA to the FDA by summer 2026.
Disproves:The company delays the NDA submission beyond the end of summer 2026.
Why it matters: Updates on the $2 billion share repurchase program could show management's confidence in the stock. It may also indicate future growth.
Confirms:They announced share buybacks of at least $1 billion under the ASR program.
Disproves:There are no updates or signs of share repurchases in the next quarter.
Why it matters: A drop in sector revenue growth could impact UTHR's growth outlook and investor sentiment.
Confirms:Sector revenue growth reported below its median.
Disproves:Sector revenue growth remains at or above its median.
Why it matters: Revenue growth below 10% would signal a slowdown in company momentum and sector trends.
Confirms:Q2 revenue growth reported below 10% year over year.
Disproves:Q2 revenue growth stays at or above 10% year over year.
Why it matters: Steady revenue growth from Tyvaso DPI would help the company's plans. It would also aid overall revenue recovery.
Confirms:Tyvaso DPI revenues were above $340 million in Q2. This indicates continued growth.
Disproves:Tyvaso DPI revenues were below $330 million in Q2. This suggests a slowdown.
Why it matters: Submitting the TETON-1 study results for FDA review could expand Tyvaso's market. This would support United Therapeutics' growth in treating IPF.
Confirms:A press release confirmed the submission of the New Drug Application for Tyvaso. This will happen by the end of summer.
Disproves:There was no news about the New Drug Application for Tyvaso.
Why it matters: Progress on ralinepag could improve the product lineup and boost future revenue.
Confirms:Announcement of the NDA submission for ralinepag to the FDA in the second half of 2026.
Disproves:No news or delays in ralinepag progress.
